News

News


23 Jul 2012
Yesterday, efficacy data from the first novel regimen trial (NC001) were published in the Lancet . The results found that the regimen containing PA-824, moxifloxacin, and pyrazinamide, could kill more than 99 percent of patients’ TB bacteria within two weeks and could be more effective than...
22 Jul 2012
TB REACH, an initiative of the Stop TB Partnership to promote early and increased TB case detection, today has launched its call for applications for Wave 3 funding. Partners of the Stop TB Partnership, national TB programmes, HIV programmes, local and international NGOs, civil society and...
8 Jul 2012
Inaugural entrants showcase successful new approaches Thank you to all who submitted entries to the first InnovateTB contest. We are delighted to be able to help promote them as an ongoing effort of the InnovateTB Library. At the request of our stakeholders, we divided the winners into three...
4 Jul 2012
Structure of Bedaquiline This week it was announced the Janssen Pharmaceuticals, Inc., a pharmaceutical company of Johnson & Johnson, filed a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for their drug Bedaquiline (a.k.a. TMC-207). For additional information on...
1 Jul 2012
This post originally appeared on NPR – click here to listen to the interview and read the full story Marcus Samuelsson owns two restaurants in New York City and two restaurants in Sweden. He’s cooked for President Obama and prime ministers, served as a judge on Top Chef and Chopped , and recently...
18 Jun 2012
This week we highlight an interview with Jeannine Uwimana, a public health specialist from the University of the Western Cape and TB/HIV Care Association in South Africa. She discusses her work in developing models for community-based programs to enhance TB and HIV collaborative activities.
13 Jun 2012
The Stop TB Partnership made two exciting announcements today: 1. US$ 40 million committed to roll-out of Xpert The executive board of UNITAID today approved funding of US$ 30 million to scale up access to Xpert MTB/RIF, and reduce the cost of its use. In addition, the Stop TB Partnership’s TB...
6 Jun 2012
Delamanid (OPC-67683) This week, efficacy data from the recently completed Phase 2 randomized placebo-controlled trial in MDR patients evaluating delamanid with background treatment compared to placebo with background treatment was published yesterday in the New England Journal of Medicine ...
24 May 2012
For this week’s update, we highlight three recent articles that look at repurposing and optimizing drugs already on the market or looking at novel targets and drug classes for TB. Dooley KE, Mitnick C, Degroote MA, Obuku E, Belitsky V, Hamilton CD, Makhene M, Shah S, Brust JC, Durakovic N,...
30 Apr 2012
The latest news from the Stop TB Partnership. You may also download a .pdf version by clicking here . WORLD TB DAY NEWS Childhood tuberculosis neglected, despite available remedies TB often goes undiagnosed in children because they lack access to care, or because health workers don’t recognize the...
30 Apr 2012
World TB Day Congressional Briefing Tuberculosis – We Can Beat this Global Killer Wednesday, March 21, 2012 A briefing and update on tuberculosis (TB), a disease that is curable but still takes the lives of 4,000 people each day and is the number one killer of people living with HIV. Special areas...
16 Apr 2012
Dr. Gill Black Summary: Dr. Gill Black is the co-founder and Director of Health and Welfare at The Sustainable Livelihoods Foundation (SLF). In this inteview, we discuss with Dr. Black one of SLF’s groundbreaking projects that uses drama to engage local communities around issues related to TB and...
10 Apr 2012
This week, we are highlighting two articles published online in the Journal of Infectious Diseases in March. The first article by Coxon, et al., looks at the benefits and limitations of the two main approaches to compound discovery for TB, target-based and phenotypic-based. The second article by...
28 Mar 2012
Click here to access publication. The WGND Strategic Plan 2011-2015 is an update of the “New Drugs” section of the Global Plan to Stop TB: 2011-2015 . It describes the progress, gaps, and vision of the WGND and the TB drug development field as a whole. Since its inception, the WGND has served as a...
26 Mar 2012
The 243rd American Chemistry Society National Meeting and Exposition is being held in San Diego, California, from March 26 to March 29. There are several presentations on tuberculosis. Here are the abstracts of a few of the talks. The first item received news coverage and discusses two approved...

Pages